Skip to main content
Fig. 2 | BMC Cardiovascular Disorders

Fig. 2

From: Trimethylamine-N-oxide has prognostic value in coronary heart disease: a meta-analysis and dose-response analysis

Fig. 2

The relationship between TMAO plasma levels and incidence of MACE. In ACS and chronic CHD patients (a); in CHD patients with in-hospital observation and a follow-up of 1–3 years and ≥ 4 years (b). ACS, acute coronary syndrome; CC, Cleveland acute coronary syndrome cohort; CHD, coronary heart diseases; CI, confidence interval; HR, hazard ratio; MACE, major adverse cardiovascular event; SC, Swiss ACS cohort; TMAO, trimethylamine-N-oxide

Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us